Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Express Scripts
Colorcon
Dow
Johnson and Johnson

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,726,918

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,726,918 protect, and when does it expire?

Patent 6,726,918 protects OZURDEX and is included in one NDA.

This patent has eighteen patent family members in twelve countries.

Summary for Patent: 6,726,918
Title: Methods for treating inflammation-mediated conditions of the eye
Abstract:Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 .mu.g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 .mu.g/ml dexamethasone for at least about three weeks.
Inventor(s): Wong; Vernon G. (Menlo Park, CA), Hu; Mae W. L. (Los Altos Hills, CA)
Assignee: Oculex Pharmaceuticals, Inc. (Sunnyvale, CA)
Application Number:09/693,008
Patent Claim Types:
see list of patent claims
Use; Device;

Drugs Protected by US Patent 6,726,918

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan OZURDEX dexamethasone IMPLANT;INTRAVITREAL 022315-001 Jun 17, 2009 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF MACULAR EDEMA   Start Trial
Allergan OZURDEX dexamethasone IMPLANT;INTRAVITREAL 022315-001 Jun 17, 2009 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF UVEITIS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Moodys
Express Scripts
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.